These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32513651)

  • 1. Response to: 'Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak' by Holubar
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Apr; 80(4):e57. PubMed ID: 32513651
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak.
    Holubar J; Le Quintrec M; Letaief H; Faillie JL; Pers YM; Jorgensen C
    Ann Rheum Dis; 2021 Apr; 80(4):e56. PubMed ID: 32513650
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Mar; 80(3):e36. PubMed ID: 32475832
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to: 'Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 May; 80(5):e78. PubMed ID: 32759253
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to 'Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic' by Chuah
    Mathian A; Amoura Z
    Ann Rheum Dis; 2022 Aug; 81(8):e145. PubMed ID: 32883652
    [No Abstract]   [Full Text] [Related]  

  • 6. Response to: 'Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India' by Goyal
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 May; 80(5):e72. PubMed ID: 32669304
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Feb; 80(2):e26. PubMed ID: 32451345
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon
    Konig MF; Gianfrancesco M; Yazdany J; Robinson PC
    Ann Rheum Dis; 2021 Apr; 80(4):e55. PubMed ID: 32475834
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to: 'Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Mar; 80(3):e34. PubMed ID: 32471900
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydroxychloroquine dosing in systemic lupus erythematosus: response to 'Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis
    Fanouriakis A; Bertsias G; Boumpas DT
    Ann Rheum Dis; 2020 Aug; 79(8):e91. PubMed ID: 31201171
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Apr; 80(4):e53. PubMed ID: 32616603
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak.
    So H; Szeto CC; Tam LS
    Ann Rheum Dis; 2021 Jun; 80(6):e97. PubMed ID: 32581085
    [No Abstract]   [Full Text] [Related]  

  • 13. Patients with lupus with COVID-19: University of Michigan experience.
    Wallace B; Washer L; Marder W; Kahlenberg JM
    Ann Rheum Dis; 2021 Mar; 80(3):e35. PubMed ID: 32475835
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to: 'Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus' by Wu
    Fanouriakis A; Bertsias G; Boumpas DT
    Ann Rheum Dis; 2022 May; 81(5):e76. PubMed ID: 32434817
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 May; 80(5):e70. PubMed ID: 32737109
    [No Abstract]   [Full Text] [Related]  

  • 16. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic.
    Peschken CA
    J Rheumatol; 2020 Jun; 47(6):787-790. PubMed ID: 32269064
    [No Abstract]   [Full Text] [Related]  

  • 17. The Role of Immunosuppression in the Development of COVID-19 in Systemic Lupus Erythematosus Patients: A Brief Report.
    Damirchi M; Aghaie M; Sedighi S; Tavassoli S; Roshandel G; Hassani M; Abdolahi N
    Iran J Med Sci; 2023 Jan; 48(1):91-97. PubMed ID: 36688192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to: 'COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases' by Lopez-Medina
    Bozzalla Cassione E; Zanframundo G; Biglia A; Codullo V; Montecucco C; Cavagna L
    Ann Rheum Dis; 2021 Apr; 80(4):e51. PubMed ID: 32503850
    [No Abstract]   [Full Text] [Related]  

  • 19. Are patients with systemic lupus erythematosus at increased risk for COVID-19?
    Favalli EG; Gerosa M; Murgo A; Caporali R
    Ann Rheum Dis; 2021 Feb; 80(2):e25. PubMed ID: 32451344
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of SARS-CoV-2 coronavirus infection in patients with systemic lupus erythematosus from a single center in Catalonia.
    Espinosa G; Prieto-González S; Llevadot M; Marco-Hernández J; Martínez-Artuña A; Pérez-Isidro A; Rifé E; Cervera R
    Clin Rheumatol; 2021 May; 40(5):2057-2063. PubMed ID: 33677725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.